Health

Long-acting regimen noninferior to daily ART for HIV-1

(HealthDay)—Monthly long-acting (LA) cabotegravir (CAB) and rilpivirine (RPV) are noninferior to daily regimens for patients with HIV-1, according to two studies presented at the Conference on Retroviruses and Opportunistic ...

HIV & AIDS

Dolutegravir plus abacavir-lamivudine beats combo therapy

(HealthDay)—For patients with HIV-1 infection and HIV-1 RNA of 1,000 copies per mL or more, treatment with dolutegravir plus abacavir-lamivudine (DTG-ABC-3TC) is more effective through 48 weeks than combination therapy ...

Medications

Interaction between molecules key to dangerous drug reaction

University of Florida researchers have helped identify the underlying cause of a genetically derived, potentially fatal reaction to an anti-HIV medication, and have begun creating a less dangerous form of the drug.